ArticleCancer research2020
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Regulatory role of the METTL3/MALAT1 axis in multiple myeloma progression.Journal of bone oncology · 2025Article
- Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects.Frontiers in immunology · 2025Review
- The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7.Cardiovascular diabetology · 2024Review
- Investigation of Non-Coding RNA-Related Autophagy Alterations in Drug-Resistant Multiple Myeloma Plasma Cells.Iranian journal of pathology · 2024Article
- Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.Signal transduction and targeted therapy · 2023Review
- Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.International journal of molecular sciences · 2023Review
- Tumor suppressor genes are reactivated by miR-26A1 via enhancer reprogramming in NSCLC.Human molecular genetics · 2023Article
- Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.International journal of molecular sciences · 2022Review
- Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.International journal of molecular sciences · 2022Article
- Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies.Biomolecules · 2022Review
- MiRNA as a Potential Target for Multiple Myeloma Therapy-Current Knowledge and Perspectives.Journal of personalized medicine · 2022Review
- Role of microRNAs in B-Cell Compartment: Development, Proliferation and Hematological Diseases.Biomedicines · 2022Review
- Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.International journal of molecular sciences · 2022Review
- Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.Cancer science · 2022Article
- Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.International journal of biological sciences · 2022Review
- Glycopolymer-Wrapped Carbon Nanotubes Show Distinct Interaction of Carbohydrates With Lectins.Frontiers in chemistry · 2022Article
- Down-regulation of circ_0058058 suppresses proliferation, angiogenesis and metastasis in multiple myeloma through miR-338-3p/ATG14 pathway.Journal of orthopaedic surgery and research · 2021Article
- One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.Epigenomes · 2021Review
- LBX2-AS1 as a Novel Diagnostic Biomarker and Therapeutic Target Facilitates Multiple Myeloma Progression by Enhancing mRNA Stability of LBX2.Frontiers in molecular biosciences · 2021Article
- The Circular Life of Human CD38: From Basic Science to Clinics and Back.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 2 countries.
Yi Hu *Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-5432-1438
Huimin Liu *Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Chuanfeng FangDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Chen LiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0001-6110-3714
Fjorela XhyliuDepartment of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, Ohio.
Hayley DysertDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Juraj BodoDepartment of Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Gabriel HabermehlDepartment of Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Benjamin E RussellDepartment of Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Wenjun LiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0001-6110-3714
Marcia ChappellDepartment of Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Xiaofeng JiangDepartment of Clinical Laboratory, The Fourth Hospital of Harbin Medical University, Harbin, China.
Sarah L OndrejkaDepartment of Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Eric D HsiDepartment of Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Jaroslaw P MaciejewskiDepartment of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Qing YiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Kenneth C AndersonJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Nikhil C MunshiJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Geyou AoDepartment of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, Ohio.ORCID 0000-0002-9932-3971
Jason N ValentDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Jianhong LinDepartment of Genetics and Genome Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio. zhaoj4@ccf.org jxl1984@case.edu.
Jianjun ZhaoDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. zhaoj4@ccf.org jxl1984@case.edu.
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · USCleveland State University · USHarbin Medical University · CNYuhuangding Hospital · CNCase Western Reserve University · USDana-Farber Cancer Institute · USHebei Agricultural University · CNVA Boston Healthcare System · US
Funding
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5MTRAINING IN COMPUTATIONAL GENOMIC EPIDEMIOLOGY OF CANCERR25CA094186 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LI, LI · 2002 to 2016
$6.8MComputational Genomic Epidemiology of Cancer (CoGEC) Training ProgramT32CA094186 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Thomas Louis LaFramboise, Rong Xu · 2017 to 2026
$2.6MElucidating the role of microRNAs in the initiation of multiple myelomaR00CA172292 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI ZHAO, JIANJUN · 2015 to 2017
$747kLTQ-Orbitrap Velos instrumentS10RR031537 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLARD, BELINDA BELLE · 2011 to 2011
$600kElucidating the role of microRNAs in the initiation of multiple myelomaK99CA172292 · NCI · DANA-FARBER CANCER INST · PI ZHAO, JIANJUN · 2013 to 2014
$252kNCATS NIH HHS UL1 TR002548NCI NIH HHS K99 CA172292NCI NIH HHS R00 CA172292NCI NIH HHS R25 CA094186NCI NIH HHS T32 CA094186NCRR NIH HHS S10 RR031537
Abstract
Multiple myeloma is an incurable refractory hematologic malignancy arising from plasma cells in the bone marrow. Here we investigated miR-26a function in multiple myeloma and tested single-wall carbon nanotube delivery of miR-26a
Indexed as
ADP-ribosyl Cyclase 1AnimalsAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Agents, ImmunologicalApoptosisCell MovementCell ProliferationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHeterograftsHumansMiceMicroRNAsMultiple MyelomaADP-ribosyl Cyclase 1Antibodies, MonoclonalAntineoplastic AgentsAntineoplastic Agents, ImmunologicaldaratumumabMicroRNAsMIRN26 microRNA, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.